TABLE 3.

Meta analysis estimate $\widehat{\text{OR}}$ for various sets of patients: (A) all patients, (B) patients not treated with rt-PA, and (C) patients who started the highest dose of citicoline from studies reported by Secades et al. (2016)²⁰, and (D) a meta analysis by Davalos et al. (2012)²¹. The sample sizes (n₁, n₂) for the citicoline and placebo groups are noted under the p-values if the study contributes a subset of subjects to the analysis.

		Meta Analyses by Secades et al. (2016)
Study†	Sample Size (n1, n2)	(A) All patients	(B) Not on rt-PA	(C) On highest dose	(D) Dávalos 2012 study
Boudouresques 1980	(23, 22)	.0092	.0092
Goas 1980	(31,33)	.0264	.0264
Corso 1982	(17, 16)	.9943	.9943
Tazaki 1988	(136, 136)	.00005	.00005		.00005
USA 1 1997	(193, 64)	.3169	.3169	.2353	.3169
			(65, 64)
USA 2 1999	(267, 127)	.4440	.4440		.4440
USA 3 2000	(52, 48)	.9085	.9085		.9085
USA 4 2001	(452, 446)	.0240	.0240	.0044	.0240
			(396, 368)
Alviarez 2007	(29, 30)	.3668	.3668	.3668
ICTUS 2012	(1148, 1150)	.5384	.7153	.7153	.5384
			(613, 615)	(613, 615)
Estimates
MLE ${\widehat{\text{OR}}}_{MLE}$		1.10	1.13	1.09	1.09
95% CI		(1.03, 1.17)	(1.04, 1.21)	(.99, 1.19)	(1.02, 1.16)
${\widehat{\text{OR}}}_T$‡		1.10	1.13	1.07	1.08
95% CI		(1.02, 1.17)	(1.04, 1.21)	(0.97, 1.18)	(1.01, 1.16)
Bayes ${\widehat{\text{OR}}}_B$		1.09	1.12	1.09	1.08
95% CI		(1.02, 1.17)	(1.03, 1.21)	(1.01, 1.19)	(1.01, 1.16)

^†Detailed references for the studies are in Secades et al. (2016)²⁰.

^‡MLE based on truncated distribution (11).